NO920703L - Fusjonsproteiner som omfatter gm-csf og il-3 - Google Patents

Fusjonsproteiner som omfatter gm-csf og il-3

Info

Publication number
NO920703L
NO920703L NO92920703A NO920703A NO920703L NO 920703 L NO920703 L NO 920703L NO 92920703 A NO92920703 A NO 92920703A NO 920703 A NO920703 A NO 920703A NO 920703 L NO920703 L NO 920703L
Authority
NO
Norway
Prior art keywords
csf
fusion proteins
proteins including
fusion
alone
Prior art date
Application number
NO92920703A
Other languages
English (en)
Other versions
NO301888B1 (no
NO920703D0 (no
Inventor
Benson M Curtis
Linda S Park
David J Cosman
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO920703D0 publication Critical patent/NO920703D0/no
Publication of NO920703L publication Critical patent/NO920703L/no
Publication of NO301888B1 publication Critical patent/NO301888B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO920703A 1989-08-22 1992-02-21 Fremgangsmåte for fremstilling av fusjonsproteiner som omfatter GM-CSF og IL-3, DNA-sekvens som koder for slike og rekombinant ekspresjonsvektor som omfatter en slik DNA-sekvens NO301888B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39714689A 1989-08-22 1989-08-22
PCT/US1990/004599 WO1991002754A1 (en) 1989-08-22 1990-08-14 Fusion proteins comprising gm-csf and il-3

Publications (3)

Publication Number Publication Date
NO920703D0 NO920703D0 (no) 1992-02-21
NO920703L true NO920703L (no) 1992-04-14
NO301888B1 NO301888B1 (no) 1997-12-22

Family

ID=23570012

Family Applications (1)

Application Number Title Priority Date Filing Date
NO920703A NO301888B1 (no) 1989-08-22 1992-02-21 Fremgangsmåte for fremstilling av fusjonsproteiner som omfatter GM-CSF og IL-3, DNA-sekvens som koder for slike og rekombinant ekspresjonsvektor som omfatter en slik DNA-sekvens

Country Status (11)

Country Link
EP (1) EP0489116B1 (no)
JP (1) JP3115318B2 (no)
AT (1) ATE103932T1 (no)
AU (1) AU632372B2 (no)
DD (1) DD297188A5 (no)
DE (1) DE69007975T2 (no)
DK (1) DK0489116T3 (no)
ES (1) ES2055445T3 (no)
FI (1) FI920764A0 (no)
NO (1) NO301888B1 (no)
WO (1) WO1991002754A1 (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU651152B2 (en) * 1990-08-29 1994-07-14 Genetics Institute, Llc Multidomain hematopoiesis stimulators
WO1992006116A1 (en) * 1990-09-28 1992-04-16 Ortho Pharmaceutical Corporation Hybrid growth factors
JPH06508985A (ja) * 1991-02-27 1994-10-13 クリエイティブ　バイオモレキュルズ　インコーポレイテッド 富セリンペプチドリンカー
DE69231467T2 (de) 1991-05-10 2001-01-25 Genentech, Inc. Auswählen von agonisten und antagonisten von liganden
US5856115A (en) * 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
DE69227693T2 (de) * 1991-08-30 1999-07-22 Fred Hutchinson Cancer Research Center, Seattle, Wash. Hybride cytokine
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
US6361977B1 (en) 1992-11-24 2002-03-26 S. Christopher Bauer Methods of using multivariant IL-3 hematopoiesis fusion protein
AU5670994A (en) 1992-11-24 1994-06-22 G.D. Searle & Co. Interleukin-3 (il-3) mutant polypeptides
US6057133A (en) * 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US7091319B1 (en) 1992-11-24 2006-08-15 Bauer S Christopher IL-3 variant hematopoiesis fusion protein
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5501962A (en) * 1993-06-21 1996-03-26 G. D. Searle & Co. Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
ITFI940106A1 (it) * 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
NZ289721A (en) * 1994-07-07 1997-11-24 Immunex Corp Fusion proteins comprising gm-csf and antigens; their expression on yeast
US6017523A (en) * 1995-06-06 2000-01-25 G.D. Searle & Co. Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US20100209341A1 (en) 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
KR20130032866A (ko) * 2010-02-18 2013-04-02 더 유니버시티 오브 멜버른 만성 염증 상태의 치료
CA2861927C (en) 2012-01-20 2021-01-26 Vib Vzw Targeted mutant alpha-helical bundle cytokines
AU2014292371B2 (en) 2013-07-18 2018-03-29 Centre Hospitalier Regional Universitaire De Montpellier Fusokines involving cytokines with strongly reduced receptor binding affinities
WO2015007520A1 (en) 2013-07-19 2015-01-22 Vib Vzw Targeting of cytokine antagonists
ES2714504T3 (es) 2013-07-19 2019-05-28 Vib Vzw Miembros de la familia il-1 modificados dirigidos
KR102268688B1 (ko) 2013-07-19 2021-06-24 브이아이비 브이지더블유 표적화된 변형된 tnf 패밀리 구성원
JP6067540B2 (ja) * 2013-11-07 2017-01-25 日本曹達株式会社 防蟻性能試験用器具
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
DK3411398T3 (da) 2016-02-05 2024-06-24 Orionis Biosciences BV Målrettede terapeutiske midler og anvendelse heraf
WO2017153402A1 (en) 2016-03-07 2017-09-14 Vib Vzw Cd20 binding single domain antibodies
CA3023883A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
CN109563141A (zh) 2016-05-13 2019-04-02 奥里尼斯生物科学公司 对非细胞结构的治疗性靶向
US11084859B2 (en) 2016-10-24 2021-08-10 Orionis Biosciences BV Targeted mutant interferon-gamma and uses thereof
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
US11246911B2 (en) 2017-02-07 2022-02-15 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
WO2019032663A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. PD-1 AND PD-L1 BINDING AGENTS
JP7347899B2 (ja) 2017-08-09 2023-09-20 オリオンズ バイオサイエンス インコーポレイテッド Ｃｄ８結合物質
CA3069992A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. Clec9a binding agents and use thereof
WO2020033646A1 (en) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
CA3133643A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Therapeutic interferon alpha 1 proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0167548B1 (en) * 1983-12-23 1993-02-10 The Australian National University Cloning of cdna and expression of murine-interleukin-3
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
DE3712985A1 (de) * 1987-04-16 1988-11-03 Hoechst Ag Bifunktionelle proteine
EP0276846A3 (en) * 1987-01-29 1989-07-26 Zymogenetics, Inc. Colony-stimulating factor derivatives
OA09736A (en) * 1987-02-18 1993-11-30 Schering Biotech Corp "Human interleukin-3 and muteins thereof".

Also Published As

Publication number Publication date
DE69007975D1 (de) 1994-05-11
JP3115318B2 (ja) 2000-12-04
AU632372B2 (en) 1992-12-24
DK0489116T3 (da) 1994-05-02
AU6424090A (en) 1991-04-03
WO1991002754A1 (en) 1991-03-07
JPH05500806A (ja) 1993-02-18
ATE103932T1 (de) 1994-04-15
NO301888B1 (no) 1997-12-22
FI920764A0 (fi) 1992-02-21
ES2055445T3 (es) 1994-08-16
EP0489116B1 (en) 1994-04-06
EP0489116A1 (en) 1992-06-10
DD297188A5 (de) 1992-01-02
DE69007975T2 (de) 1994-07-21
NO920703D0 (no) 1992-02-21

Similar Documents

Publication Publication Date Title
NO920703L (no) Fusjonsproteiner som omfatter gm-csf og il-3
MX9203426A (es) Proteinas de fusion que comprenden gm-csf e il-3.
DE69933216D1 (de) Erythropoietin-analog-menschliches serum-albumin fusionsprotein
IS5887A (is) Interferón-beta bræðsluprótín og notkun þeirra
ES2031806T3 (es) Factor de permeabilidad vascular humano.
TR199600357A2 (tr) Rekombinant simanlik (Ob) proteinleri.
NO20071415L (no) OB-fusjonsproteinpreparater og fremgangsmater
DE68917323D1 (de) Expressions-Vektor für Fusions-Proteine und Immunogen-Proteine.
BR9407583A (pt) Processos para produzir uma proteina bcl-2 mutante para identificar agentes modulantes de bcl-2 candidatos um bcl-2 mutante e proteinas bcl-2 mutantes e para inibir a atividade repressora de morte de células de bcl-2 e polipeptideo bcl-2 mutante
DK19991D0 (da) Proteinpraeparationer
DK110190D0 (da) Alveolaere surfaktantproteiner
EP0483247A4 (en) Recombinantly produced human membrane cofactor protein (mcp)
NO953882D0 (no) Biologisk aktive polypeptidfusjonsdimerer
FI864552A (fi) Human-lysozym.
ES2084658T3 (es) Genes codificantes de una proteina con actividad macif humana, vectores de expresion que contienen los indicados genes, celulas transformadoras y proteinas con actividad macif humana.
FI953422A0 (fi) Autolysoivia fuusioproteiineja hyväksikäyttävät ilmentämisjärjestelmät ja uusi pelkistävä polypeptidi
NO924165D0 (no) Proteasedefisiente bakterieverter
NO891926D0 (no) Fremgangsmaate for fremstilling av stabile protein- eller peptidpreparater.
FI942467A (fi) Proteesivakaat proteiinit
MY114223A (en) Fusion proteins comprising gm-csf and il-3
DE59008693D1 (de) Gewebs-Plasminogen-Aktivator-Derivat.
DK180290D0 (da) Monoxidil-gel og fremgangsmaade til fremstilling deraf
NO903967L (no) Dihydrocaffeinsyrederivater og farmasoeytiske preparater som inneholder disse.
NO891485D0 (no) Fremgangsmaate til fremstilling av 22 kd-sgh-protein og lineaer genevektor.
ITRM920517A0 (it) Procedimento di produzione della proteina sv-iv ricombinante e proteina sv-iv ricombinante.